Meredith John T, Wait Scott, Brewer Kori L
The Brody School of Medicine at East Carolina University, Department of Emergency Medicine, Division of Research, Physician's Quadrangle, Building M, Greenville, NC 27858, USA.
Am J Emerg Med. 2003 May;21(3):173-5. doi: 10.1016/s0735-6757(02)42256-5.
We conducted a study to compare the efficacy in migraine headache of nasal sumatriptan and intravenous ketorolac. The study was a prospective, double-blind study done with a convenience sample of 29 patients presenting to the emergency department (ED) with acute migraine. Patients received either 20 mg of nasal sumatriptan or 30 mg of intravenous ketorolac. Patients scored the severity of their headache on a 100-mm visual analog scale (VAS) of pain prior to medication, and again 1 hour after medication. Differences between initial and 1-hour scores were analyzed. Before treatment, no difference existed between the groups in the intensity of headache. One hour after medication, the sumatriptan group had a decrease in pain score of 22.937 mm and the ketorolac group a decrease of 71.462 mm on the VAS. The decrease in pain score with ketorolac was significantly greater than that with sumatriptan (P < 0.001). The study therefore showed that both sumatriptan and ketorolac effectively reduced the pain associated with acute migraine headache, but that intravenous ketorolac produced a greater reduction in pain than did nasal sumatriptan.
我们开展了一项研究，以比较鼻用舒马曲坦和静脉注射酮咯酸治疗偏头痛的疗效。该研究为前瞻性双盲研究，以29例因急性偏头痛到急诊科就诊的患者作为便利样本。患者分别接受20毫克鼻用舒马曲坦或30毫克静脉注射酮咯酸治疗。患者在用药前及用药1小时后，使用100毫米视觉模拟疼痛量表（VAS）对头痛严重程度进行评分。分析用药初始和1小时后评分的差异。治疗前，两组患者头痛强度无差异。用药1小时后，舒马曲坦组VAS疼痛评分降低22.937毫米，酮咯酸组降低71.462毫米。酮咯酸组的疼痛评分降低幅度显著大于舒马曲坦组（P < 0.001）。因此，该研究表明，舒马曲坦和酮咯酸均能有效减轻急性偏头痛相关疼痛，但静脉注射酮咯酸的止痛效果优于鼻用舒马曲坦。
